GoodRx Financial Ratios
NASDAQ: GDRXTechnologyEDP ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GoodRx ratio analysis
GoodRx earned a net margin of 3.8% in FY 2025, up from 2.1% a year earlier. Gross margin was 92.8% compared with a median of 93.9% over the prior 7 years. Return on equity reached 4.9%, meaning GoodRx generated 0.05 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.79 versus 0.68 the year before, and the current ratio was 2.61. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
GoodRx financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 30.56 | 111.25 | — | — | — | — | — | — |
| Price / sales | 1.23 | 2.17 | 3.66 | 2.51 | 17.97 | 20.12 | — | — |
| Price / book | 1.59 | 2.37 | 3.61 | 2.36 | 16.11 | 15.58 | — | — |
| Gross margin | 92.8% | 93.9% | 91.1% | 91.5% | 93.7% | 94.6% | 96.4% | 97.6% |
| Operating margin | 11.0% | 8.3% | -3.6% | 0.2% | 1.8% | -50.1% | 36.0% | 31.0% |
| Net margin | 3.8% | 2.1% | -1.2% | -4.3% | -3.4% | -53.3% | 17.0% | 17.6% |
| Free cash flow margin | 20.6% | 23.1% | 18.3% | 18.6% | 23.4% | 20.1% | 21.1% | 17.8% |
| Return on equity (ROE) | 4.9% | 2.3% | -1.2% | -4.0% | -3.0% | -41.3% | — | — |
| Return on assets (ROA) | 2.2% | 1.2% | -0.6% | -2.0% | -1.6% | -20.0% | 17.1% | — |
| Debt / equity | 0.79 | 0.68 | 0.86 | 0.81 | 0.80 | 0.94 | — | — |
| Current ratio | 2.61 | 5.32 | 7.12 | 12.05 | 13.42 | 18.24 | 2.59 | — |
| Revenue growth | 0.6% | 5.6% | -2.1% | 2.8% | 35.4% | 41.9% | 55.6% | — |
| EPS growth | 125.0% | — | — | — | — | -694.4% | 50.0% | — |